The main purpose of this study is to compare how one 50mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe liver problems. The study is also being done to 1) check on how well the study drug is tolerated by healthy subjects versus those with liver problems and 2) to check if liver impairment affects how the study drug binds to protein in the blood.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
33
Subjects will be administered a single oral dose of 50 mg eltrombopag.
GSK Investigational Site
Gainesville, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Randwick, Sydney, New South Wales, Australia
GSK Investigational Site
Adelaide, South Australia, Australia
Plasma levels and protein binding of eltrombopag
Time frame: Day 1 to Day 6
Safety will be monitored by: - clinical lab tests - vital signs - electrocardiograms - monitoring for adverse events - physical exams - eye exams
Time frame: throughout the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Christchurch, New Zealand